BRPI0507645A - anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico - Google Patents
anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólicoInfo
- Publication number
- BRPI0507645A BRPI0507645A BRPI0507645-5A BRPI0507645A BRPI0507645A BR PI0507645 A BRPI0507645 A BR PI0507645A BR PI0507645 A BRPI0507645 A BR PI0507645A BR PI0507645 A BRPI0507645 A BR PI0507645A
- Authority
- BR
- Brazil
- Prior art keywords
- bone disorder
- metabolic bone
- detecting
- treating
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N37/00—Details not covered by any other group of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- General Physics & Mathematics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
Abstract
ANTICORPO, MéTODO DE DETECTAR UM DISTúRBIO óSSEO METABóLICO, KIT PARA DETECTAR UM DISTúRBIO óSSEO METABóLICO, COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DE UM DISTúRBIO óSSEO METABóLICO, E, MéTODO DE TRIAR UMA SUBSTáNCIA EFETIVA PARA TRATAR E/OU PREVENIR UM DISTúRBIO óSSEO METABóLICO Um método de detecção de distúrbio metabólico ósseo pelo uso de um gene fortemente expressado em osteoclastos; um método de triagem de um composto possuindo um efeito de tratamento e/ou de prevenção de distúrbios metabólico ósseo; e uma composição medicinal para o tratamento e/ou a prevenção de distúrbio metabólico ósseo. A saber, um método de detecção de distúrbio metabólico ósseo pelo uso da expressão de gene DC-STAMP de humano como uma indicação; uma composição medicinal contendo Anticorpo que especificamente reconhece DC-STAMP de humano e possui uma atividade de inibição da formação de osteoclastos, etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004035216 | 2004-02-12 | ||
PCT/JP2005/002373 WO2005078087A1 (ja) | 2004-02-12 | 2005-02-09 | 破骨細胞関連タンパク質を標的とした抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507645A true BRPI0507645A (pt) | 2007-07-10 |
Family
ID=34857678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507645-5A BRPI0507645A (pt) | 2004-02-12 | 2005-02-09 | anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico |
Country Status (10)
Country | Link |
---|---|
US (2) | US8980272B2 (pt) |
EP (1) | EP1715038B1 (pt) |
JP (1) | JP5078104B2 (pt) |
KR (1) | KR101132579B1 (pt) |
CN (1) | CN1942581B (pt) |
BR (1) | BRPI0507645A (pt) |
CA (1) | CA2555848A1 (pt) |
ES (1) | ES2428791T3 (pt) |
TW (1) | TWI359026B (pt) |
WO (1) | WO2005078087A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
EP2438962A3 (en) | 2006-02-13 | 2012-07-18 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
USRE49444E1 (en) | 2006-10-03 | 2023-03-07 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
US7803770B2 (en) | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
PT2957278T (pt) * | 2006-10-03 | 2017-08-23 | Ipsen Pharma Sas | Uma composição estável compreendendo pthrp e utilizações da mesma |
ES2540733T3 (es) | 2007-10-11 | 2015-07-13 | Daiichi Sankyo Company, Limited | Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos |
JP5653909B2 (ja) | 2009-04-09 | 2015-01-14 | 第一三共株式会社 | 抗Siglec−15抗体 |
CA2760330C (en) * | 2009-04-30 | 2017-07-25 | University Of Rochester | Dc-stamp antibodies |
MX2013003828A (es) | 2010-10-05 | 2013-06-28 | Daiichi Sankyo Co Ltd | Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos. |
WO2012050154A1 (ja) * | 2010-10-13 | 2012-04-19 | 学校法人 東京女子医科大学 | 抗vdac抗体を含有する破骨細胞形成抑制剤 |
RU2014143798A (ru) | 2012-03-30 | 2016-05-27 | Дайити Санкио Компани, Лимитед | Антитело к сиглек-15 с модифицированной cdr |
IN2014KN02933A (pt) | 2012-07-19 | 2015-05-08 | Alethia Biotherapeutics Inc | |
EP4039253A1 (en) | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Methods of treating cancer |
CN105567701B (zh) * | 2015-12-18 | 2019-07-19 | 中国农业大学 | Dcstamp基因及其应用 |
EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
US10996208B2 (en) | 2017-04-28 | 2021-05-04 | Radius Health, Inc. | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
AU2019297421A1 (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD 1901-2HCL |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5331573A (en) | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
JP3622208B2 (ja) | 1993-06-11 | 2005-02-23 | 東ソー株式会社 | 骨粗鬆症治療方法及び治療薬 |
NZ332995A (en) * | 1997-04-15 | 2000-07-28 | Snow Brand Milk Products Co Ltd | A protein which binds to osteoclastogenesis inhibitory factor (OCIF) |
KR20010034840A (ko) | 1998-05-08 | 2001-04-25 | 나카노 카츠히코 | 신규한 스피로화합물 또는 그 염, 이들을 함유하는자기면역질환예방 치료제 및 ap-1 저해제 |
CA2328140C (en) * | 1998-05-14 | 2012-03-13 | Immunex Corporation | Method of inhibiting osteoclast activity |
MXPA02004825A (es) * | 1999-11-15 | 2004-08-12 | Schering Corp | Genes especificamente expresados en celulas dendriticas humanas. |
DE60235989D1 (de) * | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | Antikörper gegen opgl |
US7420000B2 (en) * | 2003-09-10 | 2008-09-02 | University Of Southern California | Amino phosphonate and amino bis-phosphonate derivatives |
TWI359026B (en) * | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
ES2540733T3 (es) | 2007-10-11 | 2015-07-13 | Daiichi Sankyo Company, Limited | Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos |
-
2005
- 2005-02-05 TW TW094103893A patent/TWI359026B/zh not_active IP Right Cessation
- 2005-02-09 BR BRPI0507645-5A patent/BRPI0507645A/pt not_active IP Right Cessation
- 2005-02-09 WO PCT/JP2005/002373 patent/WO2005078087A1/ja active Application Filing
- 2005-02-09 ES ES05710273T patent/ES2428791T3/es active Active
- 2005-02-09 EP EP05710273.3A patent/EP1715038B1/en not_active Not-in-force
- 2005-02-09 KR KR1020067016069A patent/KR101132579B1/ko not_active IP Right Cessation
- 2005-02-09 CN CN2005800110602A patent/CN1942581B/zh not_active Expired - Fee Related
- 2005-02-09 CA CA002555848A patent/CA2555848A1/en not_active Abandoned
-
2006
- 2006-08-11 US US11/503,574 patent/US8980272B2/en not_active Expired - Fee Related
- 2006-08-11 US US11/502,767 patent/US20070031421A1/en not_active Abandoned
-
2010
- 2010-10-14 JP JP2010231331A patent/JP5078104B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2555848A1 (en) | 2005-08-25 |
WO2005078087A1 (ja) | 2005-08-25 |
EP1715038A4 (en) | 2009-10-21 |
US8980272B2 (en) | 2015-03-17 |
TW200529872A (en) | 2005-09-16 |
EP1715038B1 (en) | 2013-04-24 |
EP1715038A1 (en) | 2006-10-25 |
ES2428791T3 (es) | 2013-11-11 |
US20070081974A1 (en) | 2007-04-12 |
KR20060111691A (ko) | 2006-10-27 |
US20070031421A1 (en) | 2007-02-08 |
JP5078104B2 (ja) | 2012-11-21 |
TWI359026B (en) | 2012-03-01 |
CN1942581B (zh) | 2010-09-08 |
CN1942581A (zh) | 2007-04-04 |
JP2011057682A (ja) | 2011-03-24 |
KR101132579B1 (ko) | 2012-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507645A (pt) | anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico | |
BRPI0818437B8 (pt) | anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma | |
NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
BRPI0415397A (pt) | métodos e reagentes para o tratamento de desordens imunoinflamatórias | |
CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
NO20081838L (no) | 5-lipoksygenaseaktiverende protein-(FLAP)-inhibitorer | |
CO6390109A2 (es) | Inhibidores de syk de imidazopirazina | |
BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
SG146653A1 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
EA200801164A2 (ru) | Ингибиторы протеина, активирующего 5-липоксигеназу (flap) | |
BRPI0511616A (pt) | compostos | |
BRPI0618918B8 (pt) | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea | |
BRPI0718587A2 (pt) | Uso de um composto, compostos, método de tratamento ou prevenção de doenças, processos para a preparação do composto e composição farmacêutica contendo o mesmo | |
ATE410424T1 (de) | Spirocyclische cyclohexan-derivate | |
WO2007103114A3 (en) | Notch inhibition in the treatment or prevention of atherosclerosis | |
WO2007103373A3 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
BRPI0815591A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio. | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
CL2007002887A1 (es) | Compuestos derivados de heterociclos, inhibidores de metaloproteinasa de la matriz (mmp); compuesto intermediario; composicion farmaceutica; kit farmaceutico; y uso en la prevencion y tratamiento en afecciones mediadas por metaloproteinasas de la mat | |
BRPI0607084A2 (pt) | uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto | |
BRPI0718469A2 (pt) | Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |